Amarin Corp. PLC ADR (AMRN) News

Amarin Corp. PLC ADR (AMRN): $5.40

-0.04 (-0.74%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AMRN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

Filter AMRN News Items

AMRN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AMRN News Highlights

  • For AMRN, its 30 day story count is now at 9.
  • Over the past 22 days, the trend for AMRN's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • The most mentioned tickers in articles about AMRN are PLUG and COOL.

Latest AMRN News From Around the Web

Below are the latest news stories about Amarin Corp Plc that investors may wish to consider to help them evaluate AMRN as an investment opportunity.

Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.

Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and ReimbursementDUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today outlined its new Go-to-Market strategy to accelerate growth of VASCEPA® (icosapent ethyl) in the United States, which focuses on expanding healthcare professional engagement through a new omnichannel platform, enhancing managed care access and optimizing VA

Yahoo | September 22, 2021

Amarin to Participate in September Investment Conferences

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that members of the senior leadership team will participate in two upcoming virtual investment conferences in September 2021. H. C.

Amarin | September 13, 2021

Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany

Brings groundbreaking therapy to patients in Germany with residual cardiovascular risk and marks key milestone in corporate growth strategy Brings groundbreaking therapy to patients in Germany with residual cardiovascular risk and marks key milestone in corporate growth strategy

Intrado Digital Media | September 13, 2021

5 Stocks With 195% to 467% Upside, According to Wall Street

If the high-water price target for each of the following five stocks were to come to fruition, shareholders would be looking at gains ranging from a low of 195% to as much as 467%. If you're "only" looking to triple your money, analyst Amit Dayal of H.C. Wainwright would suggest putting it to work in hydrogen fuel-cell solutions company Plug Power (NASDAQ: PLUG). Dayal's price target of $78 implies a cool 195% upside from where its shares closed this past weekend.

Yahoo | September 8, 2021

Atossa Therapeutics Has a Steep Climb Ahead of It

Atossa Therapeutics is popular with the Reddit crowd.

Will Ashworth on InvestorPlace | August 31, 2021

Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of Cardiology

VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in REDUCE-IT patients with prior Myocardial Infarction

Intrado Digital Media | August 31, 2021

Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society of Cardiology

VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data adding to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl) in patients with prior heart attack, known as myocardial infarction (MI), at risk for major adverse cardiovascular

Yahoo | August 23, 2021

Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of Cardiology

Amarin-Supported Research and Analyses from International Academic Collaborators to Be Featured in Seven PresentationsDUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new data that add to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl) in patients at risk for major adverse cardiovascular events will be presented at ESC Congress 2021, organized by the European Society of Cardiology (ESC), being h

Yahoo | August 16, 2021

Amarin Corporation plc's (NASDAQ:AMRN) Stock Is Going Strong: Have Financials A Role To Play?

Amarin's (NASDAQ:AMRN) stock is up by a considerable 19% over the past week. As most would know, fundamentals are what...

Yahoo | August 7, 2021

Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics

Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.

Yahoo | August 6, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8983 seconds.